바이오뱅킹 시장 예측(2026-2032년)

The Biobanking Market is projected to grow by USD 157.24 billion at a CAGR of 10.85% by 2032.

Biobanking Executive Summary

Biobanking has become foundational infrastructure for modern biomedical research, precision medicine, drug discovery, genomics, regenerative medicine, and public health preparedness. By collecting, processing, storing, annotating, and distributing biospecimens such as blood, tissue, DNA, RNA, cells, plasma, serum, and microbiome samples, biobanks enable researchers and clinicians to connect biological material with high-quality clinical, demographic, lifestyle, and molecular data. The sector is increasingly shaped by ethical consent models, interoperability standards, cold-chain reliability, automated storage systems, and secure data governance aligned with recognized biospecimen and laboratory quality practices. Demand is closely linked to the expansion of population genomics programs, oncology research, rare disease studies, longitudinal cohort research, infectious disease surveillance, and biomarker validation. As biobanking moves from sample storage toward integrated biospecimen intelligence, stakeholders are prioritizing specimen integrity, traceability, regulatory compliance, donor trust, and data quality. The strongest biobanking strategies now combine standardized pre-analytical workflows, digital inventory management, harmonized metadata, quality management systems, and privacy-preserving data access to support reproducible science and clinically relevant discoveries.

Transformative Shifts in the Biobanking Landscape

The biobanking landscape is undergoing a structural shift from repository-centered operations to data-rich, networked, and quality-driven platforms. Traditional freezer-based sample archives are being transformed through laboratory automation, robotic retrieval, cryogenic monitoring, barcode and RFID tracking, cloud-based laboratory information management systems, and standardized operating procedures designed to reduce variability in biospecimen handling. Regulatory and ethical expectations are also evolving, with greater attention to informed consent, dynamic consent, secondary use of specimens, data anonymization or pseudonymization, cross-border transfers, and equitable benefit sharing. Research programs increasingly require biospecimens linked to longitudinal clinical records, imaging, multi-omics datasets, treatment response, and real-world evidence, making metadata completeness as important as sample availability. Another major shift is the rise of decentralized and federated biobank networks, where institutions retain custody of specimens while enabling standardized discovery and controlled access across research ecosystems. Sustainability is also becoming central, as ultra-low-temperature storage and liquid nitrogen systems require robust energy management, backup planning, disaster recovery, and environmental accountability. These shifts are positioning biobanking as a strategic enabler of translational research rather than a passive support function.

Cumulative Impact of Artificial Intelligence on Biobanking

Artificial intelligence is reshaping biobanking by improving sample discovery, quality control, data harmonization, cohort identification, and operational efficiency. AI-enabled tools can support automated annotation of clinical and molecular datasets, identify inconsistencies in metadata, predict specimen degradation risks based on storage and handling variables, and optimize freezer utilization and retrieval workflows. In research settings, machine learning enhances the ability to link biospecimens with phenotypes, genotypes, imaging profiles, and treatment outcomes, accelerating biomarker discovery and patient stratification. Natural language processing can extract structured variables from clinical notes and pathology reports, improving the usability of historical biospecimen collections when appropriate governance is in place. AI also strengthens federated research models by enabling privacy-preserving analytics, where insights can be generated across distributed datasets without unnecessary movement of sensitive information. However, the cumulative impact of AI depends on data provenance, representative cohorts, transparent algorithms, auditability, cybersecurity, and compliance with privacy and research ethics requirements. Biobanks that invest in curated metadata, standardized vocabularies, consent-aware access controls, and AI governance will be better positioned to support reproducible, responsible, and high-value biomedical research.

Key Regional Insights Across Biobanking

Asia-Pacific is advancing rapidly as large population cohorts, genomic medicine initiatives, cancer research networks, and infectious disease preparedness programs increase the need for standardized biospecimen infrastructure across China, India, Japan, South Korea, Australia, and Southeast Asia. The region's population diversity offers strong scientific value for genomics, pharmacogenomics, and disease-risk studies, while also increasing the need for harmonized consent, sample export controls, data localization, and quality assurance. Europe has one of the most structured biobanking ecosystems, shaped by cross-border research collaboration, stringent data protection rules, established quality frameworks, and pan-European research infrastructures that support harmonization, responsible access, and specimen reuse. North America remains a highly developed biobanking environment, supported by mature academic medical centers, population health cohorts, clinical trial networks, advanced molecular diagnostics, and established human research protection frameworks. The United States and Canada place strong emphasis on institutional review, privacy compliance, interoperability, and biospecimen quality standards. Latin America is building biobanking capacity through cancer registries, infectious disease research, maternal and child health studies, and genomic diversity programs, with Brazil and Mexico playing important roles in regional research infrastructure development. Africa is gaining strategic importance due to its genetic diversity, infectious disease research needs, and expanding public health collaborations, although sustainable funding, cold-chain resilience, laboratory accreditation, and equitable governance remain critical priorities for long-term biobank development. The Middle East is investing in national genome programs, hereditary disease research, and healthcare modernization, with biobanking increasingly connected to precision medicine strategies, population-specific risk profiling, and rare disease research.

Key Group Insights Shaping Biobanking Priorities

NATO member countries are relevant to biobanking through health security, biodefense research, infectious disease preparedness, and resilient biomedical infrastructure, where secure data exchange, specimen traceability, and cross-institutional readiness support coordinated responses to emerging health threats. G7 countries generally demonstrate strong capabilities in academic research biobanks, clinical trial biospecimen management, national cohort studies, oncology biobanking, and standards-driven quality systems, making them influential in establishing best practices for ethical, interoperable, and reproducible biobanking. BRICS countries contribute significant biobanking relevance due to large and diverse populations, expanding biomedical research capabilities, public health priorities, and increasing adoption of genomics, although regulatory maturity, data governance, and infrastructure consistency vary across members. The European Union provides one of the most advanced governance environments for biobanking, where data protection, cross-border collaboration, research ethics, and infrastructure harmonization are central to biospecimen access and reuse. ASEAN biobanking activity is supported by growing clinical research capacity, infectious disease surveillance, cancer studies, and regional interest in genomic medicine, with harmonization needed across consent practices, biospecimen transport, laboratory quality, and data protection requirements. GCC countries are strengthening biobanking through national health transformation agendas, population genomics, rare disease research, and investments in precision medicine infrastructure, with particular focus on inherited disorders, consanguinity-associated disease risk, and population-specific health insights.

Key Country Insights in Biobanking

China is expanding biobanking through large-scale genomics, hospital networks, oncology research, infectious disease preparedness, and precision medicine initiatives, with increasing focus on data governance, sample quality, and standardized clinical annotation. The United States is a leading biobanking hub due to its extensive academic medical networks, disease-specific repositories, population cohorts, clinical trial activity, and advanced molecular research infrastructure, with strong emphasis on consent, privacy, and institutional oversight. Japan combines advanced clinical research, aging-related cohorts, oncology, regenerative medicine, and high standards for sample quality, while India's biobanking relevance is strengthened by population diversity, infectious disease research, noncommunicable disease studies, and growing genomic medicine programs. Germany emphasizes quality management, pathology-linked biobanks, translational research, and standardized processes, while the United Kingdom has a mature biobanking ecosystem supported by large cohort studies, integrated health data resources, and strong governance for research access. Australia is recognized for population health research, cancer biobanking, rare disease studies, and strong ethics frameworks, and France supports biobanking through clinical research networks, cancer and rare disease programs, and structured regulatory oversight. South Korea is advancing biobanking through national biorepository systems, genomics, digital health integration, and precision medicine programs that connect biospecimens with clinical and molecular datasets. Italy and Spain contribute through hospital-based biobanks, oncology research, rare disease programs, and European collaboration frameworks, while Canada supports biobanking through population health research, cancer and chronic disease studies, Indigenous data governance considerations, and national efforts to improve interoperability and ethical access. Russia maintains capabilities in population genetics, infectious disease research, and biomedical repositories, with data governance and international collaboration shaped by national regulatory priorities. Brazil and Mexico are important Latin American contributors, driven by cancer research, infectious disease studies, metabolic disease burdens, and growing genomic diversity initiatives.

Actionable Recommendations for Biobanking Leaders

Industry leaders should prioritize biospecimen quality, data interoperability, ethical governance, and operational resilience as core pillars of biobanking strategy. Establishing standardized collection, processing, storage, and shipment protocols is essential to reduce pre-analytical variability and support reproducible research. Organizations should invest in laboratory information management systems, automated inventory tracking, temperature monitoring, and audit-ready chain-of-custody documentation to strengthen traceability and compliance. To improve research value, biobanks should enrich specimens with structured clinical, genomic, imaging, and outcome data while applying privacy-preserving access controls and consent-aware data governance. Leaders should also adopt internationally recognized quality management practices, train personnel in biospecimen science, and regularly assess freezer performance, backup power, disaster recovery, and cybersecurity readiness. For global collaboration, harmonized metadata standards, common data models, federated discovery tools, and transparent access policies can improve specimen utilization without compromising donor rights. Building public trust is equally important; clear consent communication, community engagement, return-of-results policies where appropriate, and equitable research partnerships can improve participation and long-term legitimacy. Finally, sustainability programs should address energy-efficient storage, equipment lifecycle management, and risk-based retention policies to balance scientific value with environmental and operational responsibility.

Research Methodology for Biobanking Analysis

A robust biobanking research methodology should combine primary and secondary research, regulatory review, expert validation, and evidence triangulation. Primary inputs typically include discussions with biobank directors, laboratory managers, clinical researchers, ethics committee members, pathologists, data governance specialists, cold-chain experts, and precision medicine stakeholders. Secondary research should examine peer-reviewed literature, public health agency guidance, clinical research standards, biospecimen science publications, national genomics program documentation, data protection regulations, and quality management frameworks. Methodological rigor requires separating verified developments from promotional claims, assessing the reproducibility of sources, and evaluating regional differences in consent, sample transfer, privacy, and accreditation practices. The analysis should map biobanking workflows across collection, processing, storage, annotation, access, distribution, and disposal while considering biospecimen types, disease areas, end users, technology adoption, and governance models. Findings should be validated through cross-source comparison to ensure consistency across scientific publications, regulatory documents, and expert perspectives. This evidence-led approach supports an objective understanding of biobanking trends, operational priorities, risk factors, and strategic opportunities without relying on speculative sizing or forecasting.

Conclusion

Biobanking is evolving into a critical infrastructure layer for precision medicine, translational research, population health, and pandemic preparedness. Its value increasingly depends not only on stored specimens but also on biospecimen quality, standardized metadata, ethical consent, secure data linkage, and the ability to support multi-institutional research. Regional ecosystems are progressing at different speeds, yet common priorities are emerging worldwide: harmonization, automation, privacy protection, sustainability, and responsible use of artificial intelligence. Countries and institutions that strengthen quality systems, interoperability, community trust, and resilient cold-chain operations will be better positioned to accelerate biomarker discovery, improve patient stratification, and support evidence-based healthcare innovation. The future of biobanking will be defined by trusted, connected, and data-enabled repositories that transform biological samples into actionable scientific insight while protecting donor rights and research integrity.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biobanking Market, by Offering

• 7.1. Introduction
• 7.2. Product
  • 7.2.1. Biobanking Equipment
    • 7.2.1.1. Automated Sample Storage Systems
    • 7.2.1.2. Cryogenic Storage Systems
    • 7.2.1.3. Incubators & Centrifuges
    • 7.2.1.4. Refrigerators & Freezers
    • 7.2.1.5. Sample Transport & Packaging Units
  • 7.2.2. Consumables
• 7.3. Services
  • 7.3.1. Consent & Regulatory Compliance Services
  • 7.3.2. Data Management & Bioinformatics
  • 7.3.3. Sample Collection & Processing Services
  • 7.3.4. Sample Storage Services
  • 7.3.5. Sample Transport & Logistics
• 7.4. Software

8. Biobanking Market, by Biobank Type

• 8.1. Introduction
• 8.2. Physical Biobanks
• 8.3. Virtual Biobanks

9. Biobanking Market, by Sample Type

• 9.1. Introduction
• 9.2. Blood
  • 9.2.1. Plasma
  • 9.2.2. Serum
  • 9.2.3. Whole Blood
• 9.3. Cells
• 9.4. DNA/RNA
• 9.5. Tissue

10. Biobanking Market, by Application

• 10.1. Introduction
• 10.2. Diagnostics & Therapeutics
• 10.3. Drug Discovery & Clinical Research

11. Biobanking Market, by End User

• 11.1. Introduction
• 11.2. Academic & Research Institutions
• 11.3. Contract Research Organizations (CROs)
• 11.4. Government & Public Health Agencies
• 11.5. Hospitals & Clinical Labs
• 11.6. Pharmaceutical & Biotech Companies

12. Biobanking Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Biobanking Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Biobanking Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ASKION GmbH
• 16.2. Avantor, Inc.
• 16.3. Azenta Life Sciences, Inc.
• 16.4. BioKryo
• 16.5. BioLife Solutions, Inc.
• 16.6. Charles River Laboratories International, Inc.
• 16.7. Cryoport Systems, LLC
• 16.8. Cureline, Inc.
• 16.9. Danaher Corporation
• 16.10. Eurofins Scientific SE
• 16.11. FIND
• 16.12. Firalis Molecular Precision
• 16.13. Greiner Bio-One International GmbH
• 16.14. Hamilton Company
• 16.15. Laboratory Corporation of America Holdings
• 16.16. LGC Biosearch Technologies
• 16.17. Merck KGaA
• 16.18. PerkinElmer, Inc.
• 16.19. PHC Corporation
• 16.20. Qiagen N.V.
• 16.21. Sampled
• 16.22. Sopachem BV
• 16.23. SPT Labtech Ltd
• 16.24. STEMCELL Technologies Inc.
• 16.25. Taylor-Wharton
• 16.26. Tecan Trading AG
• 16.27. Thermo Fisher Scientific Inc.
• 16.28. US Biolab Corporation, Inc.
• 16.29. VigiSolvo